In the CARTITUDE-1 clinical trial examining the overall response of ciltacabtagene autoleucel, which of the following patient subgroups benefited the most from CAR T-cell therapy?

RRMM with extramedullary plasmacytomas
RRMM with high cytogenetic risk
RRMM with ≥3 prior lines of therapy
All of the above

Congratulations to our July Winner!

Dr. L.D., Dermatologist from CT